number 120511-73-1ATC recommendations to reduce arimidex side effects L02BG03PubChem 2187DrugBank APRD00016Chemical dataFormula C17H19N5Mol. mass 293.366 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability 83-85%Protein binding 40%Metabolism 85% hepaticHalf life 72 hoursExcretion 11% renalTherapeutic considerationsPregnancy cat. ?Legal.

(INN, trade name: Arimidex®) is a drug indicated in the recommendations to reduce arimidex side effects of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer". Lancet 365 (9453): 60-2. doi:10.1016/S0140-6736(04)17666-6. PMID 15639680.[edit] External recommendations to reduce arimidex side effects - Information about Arimidex and breast cancer[hide]v • recommendations to reduce arimidex side effects • eSex hormones and related agents (primarily G03, also L02, H01C) - human endogenous in CAPSProgestogens:(receptor) PROGESTERONE,Dienogest, Desogestrel, Drospirenone, Dydrogesterone, Ethisterone, Etonogestrel, Ethynodiol diacetate, Gestodene, Gestonorone, recommendations to reduce arimidex side effects Lynestrenol, Medroxyprogesterone, Megestrol, Norelgestromin, Norethisterone, Norethynodrel, Norgestimate, Norgestrel, Norgestrienone, TiboloneSelective progesterone recommendations to reduce arimidex side effects modulator: Afimoxifene, Bazedoxifene, Clomifene, Fulvestrant, Lasofoxifene, Raloxifene, recommendations to reduce arimidex side effects ToremifeneAromatase inhibitor: Aminogluthetimide, Anastrozole, Exemestane, Formestane, Letrozole.

agonist: Buserelin, Goserelin, Histrelin, Leuprorelin, Nafarelin, Triptorelinantagonist: Abarelix.